ENLIVEN THERAPEUTICS, INC. Earnings Per Share (Basic)
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Earnings Per Share (Basic) of -$0.49 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.49.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.38.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.48.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.32.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$1.83.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$1.89.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$2.01.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$12.05.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.49 10-Q · filed 2026-08-05 | -$0.87 10-Q · filed 2026-08-05 | -$1.35 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.67 derived: net income ÷ weighted average shares · filed 2026-08-05 | ||||
| 2026-03-31 | -$0.38 10-Q · filed 2026-05-07 | -$0.85 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.18 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.65 derived: net income ÷ weighted average shares · filed 2026-08-05 | ||||
| 2025-12-31 | -$0.48 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.28 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.83 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | -$0.32 10-Q · filed 2025-11-12 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.35 10-Q · filed 2025-11-12 | -$1.82 derived: net income ÷ weighted average shares · filed 2026-08-05 | ||||
| 2025-06-30 | -$0.49 10-Q · filed 2026-08-05 | -$1.05 10-Q · filed 2026-08-05 | -$1.52 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.00 derived: net income ÷ weighted average shares · filed 2026-08-05 | ||||
| 2025-03-31 | -$0.57 10-Q · filed 2026-05-07 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.52 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.93 derived: net income ÷ weighted average shares · filed 2026-08-05 | ||||
| 2024-12-31 | -$0.46 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$0.94 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.36 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.89 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | -$0.48 10-Q · filed 2025-11-12 | -$0.89 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.43 10-Q · filed 2025-11-12 | -$1.90 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||||
| 2024-06-30 | -$0.41 10-Q · filed 2025-08-13 | -$0.95 10-Q · filed 2025-08-13 | -$1.42 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.92 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||||
| 2024-03-31 | -$0.54 10-Q · filed 2025-05-14 | -$1.01 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.52 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.93 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||||
| 2023-12-31 | -$0.47 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$0.98 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$1.38 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$2.01 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | -$0.51 10-Q · filed 2024-11-13 | -$0.91 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$1.55 10-Q · filed 2024-11-13 | -$1.96 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||||
| 2023-06-30 | -$0.41 10-Q · filed 2024-08-13 | -$1.05 10-Q · filed 2024-08-13 | -$1.44 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$2.33 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||||
| 2023-03-31 | -$0.80 10-Q · filed 2024-05-14 | -$1.10 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$2.20 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$3.46 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||||
| 2022-12-31 | -$2.91 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$6.17 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$9.04 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$12.05 10-K · filed 2024-03-14 | $0.06 10-K · filed 2023-02-10 | |||
| 2022-09-30 | -$3.27 10-Q · filed 2023-11-09 | -$0.18 10-Q · filed 2022-10-25 | -$6.14 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$9.15 10-Q · filed 2023-11-09 | -$1.17 10-Q · filed 2022-10-25 | $1.51 derived: net income ÷ weighted average shares · filed 2023-11-09 | ||
| 2022-06-30 | -$2.86 10-Q · filed 2023-08-10 | -$0.44 10-Q · filed 2022-08-03 | -$5.87 10-Q · filed 2023-08-10 | -$0.99 10-Q · filed 2022-08-03 | $0.35 derived: net income ÷ weighted average shares · filed 2023-11-09 | $3.74 derived: net income ÷ weighted average shares · filed 2023-11-09 | ||
| 2022-03-31 | -$3.01 10-Q · filed 2023-05-11 | -$0.15 derived: net income ÷ weighted average shares · filed 2023-11-09 | $1.29 derived: net income ÷ weighted average shares · filed 2023-11-09 | $16.58 derived: net income ÷ weighted average shares · filed 2023-11-09 | ||||
| 2021-12-31 | -$0.24 derived: net income ÷ weighted average shares · filed 2023-06-23 | $0.10 derived: net income ÷ weighted average shares · filed 2023-06-23 | $5.13 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$10.73 8-K · filed 2023-06-23 | -$2.37 10-K · filed 2023-02-10 | |||
| 2021-09-30 | -$0.55 10-Q · filed 2022-10-25 | -$1.26 derived: net income ÷ weighted average shares · filed 2022-10-25 | -$1.84 10-Q · filed 2022-10-25 | |||||
| 2021-06-30 | -$0.74 10-Q · filed 2022-08-03 | -$1.33 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |